Pazopanib and Weekly Topotecan in Patients Recurrent Ovarian Cancer (TOPAZ)
Status:
Unknown status
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
This clinical trial shall clarify the efficacy and safety of pazopanib in combination with
weekly topotecan in patients with platinum-resistant or intermediate platinum-sensitive
recurrent epithelial ovarian cancer, fallopian and peritoneal carcinoma